PROGEN Prostatype Genomics AB (publ)

0.0091USD0.0926 SEK · STO+3.35%Mkt Cap: 1.42M USDP/E: —

Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, glea…

Key Statistics

Company
Market Cap1.42M USD
Enterprise Value5.07M USD
Revenue (TTM)79.24K USD
Gross Profit58.47K USD
Net Income (TTM)-4.38M USD
Revenue/Share0.0015 USD
Last Price0.0091 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees7
CountrySE
SectorHealthcare
IndustryDiagnostics & Research
ISINSE0023261532
Valuation
P/E (Trailing)—
P/E (Forward)-0.93
PEG—
EV/EBITDA-1.51
EV/Revenue63.94
P/S17.90
P/B0.83
EPS (TTM)-0.03 USD
EPS (Forward)-0.0098 USD
52W Range
0.00691% of range0.2244
52W High0.2244 USD
52W Low0.0069 USD
Profitability
Gross Margin100.00%
Oper. Margin-4653.29%
EBITDA Margin0.00%
Profit Margin-7492.09%
ROE-167.75%
ROA-87.50%
ROIC-171.07%
ROCE-146.78%
Growth
Revenue Growth85.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.34M USD
CapEx (TTM)1.32M USD
FCF Margin-879.44%
FCF Yield-49.14%
Net Debt-38.58K USD
Net Debt/EBITDA0.01
Net Debt/FCF—
Balance Sheet
Debt/Equity0.20
Current Ratio0.04
Quick Ratio0.04
Book Value/Sh0.01 USD
Cash/Share0.0001 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:1000
Split DateOct 31, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.155.57M
Float544.77M
Insiders34.63%
Institutions4.18%
Technical
SMA 500.0109 (-16.5%)
SMA 2000.0454 (-79.9%)
Beta1.47
S&P 52W Chg12.00%
Avg Vol (30d)3.40M
Avg Vol (10d)1.40M
Technical Indicators
RSI (14)39.8
MACD-0.0046
MACD Signal-0.0044
MACD Hist.-0.0002
BB Upper0.0109 USD
BB Middle0.0098 USD
BB Lower0.0088 USD
BB Width21.29%
ATR (14)0.0010 USD
Vol Ratio (20d)5.21x

About Prostatype Genomics (STO: PROGEN)

›

Prostatype Genomics (STO: PROGEN) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 7 employees.

The shares were at 0.0926 SEK on 19 November 2026, down 83.5% over 52 weeks. Its 52-week range is 0.0702 SEK to 2.280 SEK: the price is 95.9% below the high and 31.9% above the low.

Its market capitalisation is 14.41M SEK.

Prostatype Genomics reports return on equity of -167.7% and revenue up 85.8% year over year.

It holds more cash than debt, a net cash position of 392.00K SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.